Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Victory Capital Holdings heads into its November earnings with short sellers rebuilding positions at a pace that stands out even as the stock slips modestly and the Street keeps nudging targets higher.
The most notable tension this week is the divergence between what analysts are doing and what short sellers are doing. Shorts have added roughly 23% to their position in a single week, lifting short interest to just over 5% of the free float. That follows a 35% build over the past month. At the same time, Barclays this morning raised its price target from $112 to $121, keeping an Equal-Weight rating, and that move follows a string of upward revisions from Morgan Stanley, Goldman Sachs, RBC, and JPMorgan over the past two months. The Street is not bearish on the stock. Yet something is drawing incremental sellers to the borrow market.
The lending side of that picture keeps the short build in context. Availability is wide at 324%, meaning roughly three shares are still available to borrow for every one already lent out. That is well off the tightest reading of the past year (172%) and sits comfortably in normal territory. Cost to borrow is just 0.49%, essentially zero. This is not a crowded, difficult, or expensive short. The rapid increase in short interest has not caused any tightening. Short sellers are adding to a position they can still put on cheaply and exit easily. That makes the build look more like a tactical hedge into earnings than a conviction short thesis.
The options market tells a similar story of modest caution rather than fear. The put/call ratio of 0.41 is fractionally below its 20-day average, and well within a standard deviation either way. Neither bulls nor bears are paying up for protection. For context, the 52-week high on the PCR was a striking 8.29, though the current reading near 0.41 is broadly in line with recent weeks. The ORTEX short score has climbed from 50 to 55.9 over the past fortnight, a move worth watching but not yet at levels that signal extreme pressure.
The analyst community has been consistently positive on price targets while staying cautious on ratings. Every major firm that has acted recently has raised targets while holding neutral-to-equal-weight ratings, a posture that says the stock has performed well but is approaching fair value. Barclays now has a $121 target against a current price of $109.58. Morgan Stanley moved to $115 in late September. Goldman's Neutral-rated target is $117. The mean price target across the desk is $120.17, implying about 9.6% upside from current levels. Valuation multiples are easing: the P/E has slipped to 13x over the past week, and EV/EBITDA has ticked down to 8.4x. Both moves are modest, but they lean in the same direction as the price, which has lost 3.75% on the week. Peers have broadly sold off in the same period: VRTS fell 3.1%, IVZ dropped 4.8%, and CG shed 4.2%, so VCTR's weekly decline looks more like sector rotation than stock-specific trouble.
One ownership note worth carrying is the activist register. Amundi S.A. is on record with a Schedule 13D/A filing, and has been flagged as an activist holder. Its last disclosed stake was 4.9% as of May 2025. Separately, the institutional picture shows BlackRock recently reported an 11.3% stake. The Vanguard Group filed a 13G/A in March 2026 showing a zero stake, down from 7.1% previously, a substantial exit that is now on the public record. As always, 13D/G disclosures are event-driven around the 5% threshold, and a holder who drops below that level may exit without filing again.
The insider data is stale at August 13, when a cluster of executives exercised options and immediately sold shares at $118.17 to cover tax withholding. These were compensation mechanics, not open-market sales, and carry limited signal. Net insider activity over the 90-day window is effectively zero.
The next earnings print is 21 days away, on November 4. History shows VCTR has moved sharply after results: the August 2026 print produced an 8.2% one-day gain and an 18.2% five-day rally. That pattern, combined with a rising short score and a near-normal but quickly building short position, makes the period between now and that release the key thing to watch.
See the live data behind this article on ORTEX.
Open VCTR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
